Cell Line-Derived Xenograft (CDX) Models

Cell line–derived xenograft (CDX) models are established by implanting human cancer cell lines into immunodeficient mice to generate tumors in vivo. These are often well-characterized cell lines that have been maintained consistently in vitro. The cancer cells are generally introduced subcutaneously, orthotopically, or intravenously into mice strains lacking functional T cells, B cells, or NK cells, such as athymic nude or severe combined immunodeficient (SCID) mice. This is necessary to prevent the host's immune system from rejecting the human tumor cells. Once established, the tumors exhibit predictable growth kinetics and patterns of progression, providing a robust platform for studying key aspects of human cancer biology, including tumor growth, angiogenesis, and metastasis. The in vivo context offered by CDX models makes them valuable tools for preclinical testing, particularly for evaluating therapeutic efficacy and exploring the molecular and genetic mechanisms that drive cancer progression. 

CDX models offer several practical and experimental advantages in preclinical oncology research. The implantation of established in vitro-cultured cancer cell lines is generally more straightforward and reproducible than working with patient-derived tumor tissue, allowing for the rapid generation of large, synchronized cohorts of tumor-bearing animals suitable for therapeutic intervention studies. Because the implanted cells can be genetically manipulated ex vivo, CDX models are well suited for functional genomics and genetic screening applications. Moreover, cell line transplant models that undergo serial in vivo passaging often develop enhanced metastatic efficiency compared with patient-derived xenografts (PDXs), providing a useful system for studying cancer dissemination. Finally, the incorporation of in vitro cell culture steps enables high-yield model production and shorter tumor latency, improving experimental throughput and overall productivity in oncology drug development.

Users who adopt the CDX model platform should be aware of several limitations as they are crucial for interpreting CDX-derived data. Extensive in vitro passaging before engraftment often leads to loss of tumor heterogeneity and enrichment of specific subclones. This is accompanied by genetic and epigenetic drift that can diminish the model’s resemblance to the original tumor. Consequently, CDX models lack many tumor microenvironment (TME) components and cannot fully reproduce the genetic diversity of patient tumors. Subclones derived from the same parental tumor cell line can exhibit substantial differences in genomic and gene expression profiles, resulting in variable drug responses across strains. These factors can reduce the predictive accuracy of CDX models for clinical outcomes. To mitigate these issues, researchers increasingly combine CDX systems with PDX models and other preclinical platforms, and incorporate strategies such as genetic reengineering, co-culture with stromal cells, and advanced molecular and imaging analyses to enhance their biological and translational relevance.